Related Experiment Video
Updated: May 30, 2026

Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Recent advances in the treatment of psoriatic arthritis
Nicolò Pipitone1, Costantino Pitzalis
1Rheumatology Unit, GKT School of Medicine, Guy's Campus, London, SE1 9RT, UK. costantino.pitzalis@kcl.ac.uk.
Abstract:
This article provides an overview of recent developments in the treatment of psoriatic arthritis with an emphasis on patent literature for the period January 1998 to December 2002. The main pathogenic pathways thought to be operative in psoriatic arthritis are highlighted and some novel compounds that can potentially interfere with such pathways at different levels are discussed. Among the new agents proposed, the inhibitors of cytokine signaling, angiogenesis, and extracellular matrix degradation appear to be of particular interest for the treatment of psoriatic arthritis resistant to conventional therapies. Finally, new formulations of existing drugs and natural remedies claimed to be useful for the treatment of psoriatic arthritis are reviewed.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Atherosclerosis III: Management
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
